Novel Antibodies & Therapeutic Proteins: Technological Challenges & Future Prospects
1. Introduction
• Historical milestones
• Polyclonal to monoclonals
• Genetic engineering, recombinant DNA technology & hybridoma technology
• Impact on the pharma industry
2. Abs: Market segmentation, size & trends
• Therapeutic Zones - Cancer, inflammation, autoimmune diseases, infectious diseases, hematological, respiratory, cardiovascular, ocular etc
• Frontrunners - Companies & products & diagnostics
• Dark horses – Companies & pipeline products
• Market trends – M&A activity, drug approvals & withdrawals
• Unmet market needs
Conclusions
3. Therapeutic Proteins: Market segmentation, size & trends
• Therapeutic Zones - Cancer, inflammation, autoimmune diseases, infectious diseases, hematological, respiratory, cardiovascular, ocular etc
• Frontrunners - Companies & products & diagnostics
• Dark horses – Companies & pipeline products
• Market trends – M&A activity, drug approvals & withdrawals
• Unmet market needs
Conclusions
4. Recent Advances in Discovery, Development & Commercialization
Briefly discuss challenges & recent advances in proteomic discovery, development and commercialization of novel Abs and therapeutic proteins
Discovery & Development
• Detection & Selection
• Improving affinity, specificity & potency, safety
• Improving delivery
Commercialization
• Cost-effective scaling up & fermentation technologies
• High throughput bioprocessing & purification
• Optimizing post translational modification for functional proteins
• Contract biomanufacturing
Conclusions
5. Regulation, IP & reimbursement
• Regulation – global harmonization
• IP, Licensing Abs & Biosimilars
• Pricing & reimbursement – US, Europe & RoW
• Conclusions
6. Industry Perspective & Future Prospects
Industry perspective
• Market sizes
• Indication
• Company profiles
Market Trends
• Production & manufacturing
• R&D & Product development
• Therapeutic growth - Patient & disease demographics
Market opportunities
• Biosimilars
• Emerging markets, US & European markets
• Co-development DxRx
• Personalised medicine
Future prospects
Conclusions